Patent will protect next generation of Qoustic Wound Therapy System(R)
MINNEAPOLIS, Oct. 9 /PRNewswire/ -- Arobella Medical, LLC, a leader in advanced ultrasonic wound care devices, today announced that its Co-founder, President and CEO Eliaz Babaev, Ph.D., has been issued a U.S. patent that covers technology employed in the next generation of the company's Qoustic Wound Therapy System(R).
The Qoustic Wound Therapy System, which offers a safe, cost-effective alternative to painful sharps debridement and other surgical modalities, is emerging as the gold standard for wound care. Light guidance contact produces a dual delivery of low-frequency ultrasound energy directly on the wound bed. This process gently, thoroughly and efficiently debrides the wound and provides stable cavitation to remove dead or diseased tissue, harmful bacteria and biofilm. Ultrasonic treatment also expedites healing by preserving healthy tissue and protecting granulation tissue, improving circulation through vasodilation and angiogenesis, and preparing the wound bed for more effective use of downstream therapies such as grafts and flaps.
"This patent, which is the first of many that are currently pending, will help protect the next generation of this product that is poised to become the latest breakthrough in wound care today," said Babaev.
The first generation of the Qoustic Wound Therapy System family was launched in February 2008.
About Arobella Medical, LLC
Arobella Medical, LLC is a Minneapolis-based medical device company
specializing in low-frequency ultrasound for wound care and other wound
management therapies. Arobella Medical is positioned to become a leader in
advanced ultrasound wound care technologies and devices. Arobella Medical
Co-founder and CEO Eliaz Babaev has more than 40 years of experience
developing, designing and commercializing medical devices that use
ultrasound, with over 40 patents worldwide. He holds a Ph.D. degree f
|SOURCE Arobella Medical, LLC|
Copyright©2008 PR Newswire.
All rights reserved